All News

Found 769,185 articles

• ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease

  5/8/2023

  ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for PMN310 for the treatment of AD.

• Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease

  5/8/2023

  Innovent Biologics, Inc. announces that the first patient with Thyroid Eye Disease has been successfully dosed in the Phase 3 study of IBI311, a recombinant anti-insulin-like growth factor-1 receptor monoclonal antibody.

• NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE

  5/8/2023

  Amgen (NASDAQ:AMGN) today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia® (denosumab) injection reduced fracture risk in patients versus oral alendronate, a frequently prescribed bisphosphonate treatment.

• Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China

  5/8/2023

  Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Hangzhou Chance Pharmaceuticals Co. Ltd. today announced that they have entered into distribution and supply agreements to provide INBRIJA ® in China.

• BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Company’s Phase 2 Clinical Trial

  5/8/2023

  BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced that it has signed a clinical trial agreement with Northwell Health, New York State's largest health care provider and private employer, and Northwell’s Feinstein Institutes for Medical Research.

• Bruker Announces Acquisition of ZONTAL to Advance the Digital Laboratory Transformation and Integrated Biopharma Data Solutions

  5/8/2023

  Bruker Announces Acquisition of ZONTAL to Advance the Digital Laboratory Transformation and Integrated Biopharma Data Solutions.

• Trevena Announces Approval of OLINVYK in China

  5/8/2023

  Trevena, Inc.(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that its partner in China, Jiangsu Nhwa, received formal approval from the National Medical Products Administration for OLINVYK.

• BioNTech Announces First Quarter 2023 Financial Results and Corporate Update

  5/8/2023

  BioNTech SE reported financial results for the three months ended March 31, 2023, and provided an update on its corporate progress.

• SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Developed its Core Algorithm to allow suitable Modelling of Human Mitochondrial Carriers for Accelerating its Cancer Drug Discovery Program

  5/8/2023

  SciSparc Ltd. announced that its joint venture MitoCareX Bio, which focuses on the discovery and development of potential drugs for cancers, rare diseases and other life-threatening conditions, succeeded to develop its core algorithm for allowing the generation of reliable 3D comparative models of human SLC25A mitochondrial carrier proteins - promising transporting targets for innovating therapies.

• Zomedica Exercises Option to Acquire Structured Monitoring Products

  5/8/2023

  Zomedica Corp., announced it has exercised its option to move forward with the acquisition of Structured Monitoring Products, Inc., the makers of VetGuardian™ zero-touch vital signs remote monitoring system, at a previously negotiated purchase price.

• KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop

  5/8/2023

  KalVista Pharmaceuticals, Inc. announced that it made two oral presentations and one poster presentation at the 13th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary.

• Boudewijn van Lent Named President and CEO of VanDeMark Chemicals

  5/8/2023

  VanDeMark Chemical, Inc., a leading global producer of life science chemistries, announced the appointment of Dr. Boudewijn van Lent as President and CEO, effective immediately.

• BiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023

  5/8/2023

  BiomX Inc. announced that the Company will host a conference call and a live audio webcast on Monday, May 15th, 2023, at 8:00 a.m. ET, to report first quarter 2023 financial results and provide business updates.

• Medigene AG to present at upcoming May 2023 investor conferences

  5/8/2023

  Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present at the following upcoming investor conferences:

• Hummingbird Bioscience to Present Preclinical Proof of Concept for Potentially First-In-Class Antibody Targeting Autoimmune Diseases

  5/8/2023

  Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, announced an upcoming poster presentation at IMMUNOLOGY2023™.

• Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

  5/8/2023

  Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, announced that the Company will release its first quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, May 11, 2023.

• Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation

  5/8/2023

  Immuron Limited is pleased to announce that the US Naval Medical Research Center has received approval from the US Food and Drug Administration to proceed with the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli developed in collaboration with Immuron.

• HAPPE Spine Announces FDA Clearance for the INTEGRATE-C™ Interbody Fusion System

  5/8/2023

  HAPPE Spine announces that the company's INTEGRATE-C™ Interbody Fusion System has received 510k clearance from the FDA.

• NYU Langone to Study Ability of Overdose Prevention Centers to Counter Unprecedented Overdose Crisis

  5/8/2023

  NYU Langone Health and Brown University's School of Public Health announced a grant award from the National Institute on Drug Abuse, part of the National Institutes of Health, to conduct research to measure the impact of some of the first publicly recognized overdose prevention centers in the United States, located in New York City and Providence, Rhode Island.

• Ascletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

  5/8/2023

  Ascletis Pharma Inc. announces that the China National Medical Products Administration has approved to conduct a Phase IIa clinical trial for ASC10 to treat respiratory syncytial virus infection.